SCG142 TCR-T cell therapy for HPV-related cancers
Part of Cancer, Digestive system, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new treatment called SCG142 TCR-T cells for cancers caused by HPV. The therapy uses your own immune cells to fight the tumor. It may help if other treatments haven't worked or are not available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a cancer caused by HPV (human papillomavirus).
- You must have at least one tumor that can be measured by a scan (like a CT or MRI).
- You must be in fairly good health, able to take care of yourself.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy (TCR-T cells) designed to target HPV-16 positive cancer cells. It may be an option for people with advanced cervical, head and neck, or anal cancer who have tried standard treatments without success.
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
This study tests a new drug, TI-0093, for people with HPV‑16 positive solid tumors (like head and neck or cervical cancer) that have come back or spread after standard treatments. The goal is to see if the drug can help shrink tumors or slow their growth.
This trial checks whether tumor samples contain HPV DNA (genetic material from the HPV virus). The goal is to improve detection in anal and cervical cancers, especially in patients planning standard radiation treatment.
This trial tests a new treatment using your own immune cells (called T cells) that are modified to target HPV-positive cancer cells. It may be an option if you have advanced cervical, head/neck, anal, penile, vulvar, or vaginal cancer that is HPV16 or HPV52 positive and has progressed after standard therapy.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.